Eisai EMEA
Leila D. is an experienced professional in the pharmaceutical and biotechnology sectors, currently serving as a Neurology Portfolio Marketing Manager at Eisai EMEA since February 2022, overseeing projects related to Psychiatry and Alzheimer's Disease. Prior roles include Senior Products Marketing Manager at LFB, where responsibilities encompassed managing critical care and rare disease products, and Products Manager at Mylan Specialty, focusing on HIV and Multiple Sclerosis products. Leila's career also features positions in market research, including a Global Business Analyst role at LFB and a Healthcare Market Research Analyst position at Stethos. With an educational background that includes a Junior MBA from ESCP Business School, Leila combines technical expertise in molecular biology with substantial marketing management experience across various therapeutic areas.
This person is not in any offices
Eisai EMEA
3 followers
At Eisai, everything we do is dedicated to giving our first thought to patients and their families through our human health care (hhc) philosophy. We are the European hub of Tokyo-based Eisai Co. Ltd., forming part of a multinational team working across a global network of R&D facilities, manufacturing sites and marketing subsidiaries. Our collective passion and dedication to patient care is the driving force behind our efforts to discover and develop innovative medicines in a variety of therapeutic areas in which a high unmet medical need remains, including oncology and neurology. Our mission is clear; we strive to make a significant long-lasting contribution to society in an ethical, compliant and sustainable way by embodying our hhc philosophy in everything we do. For more information about Eisai in the EMEA region please visit www.eisai.eu Our community guidelines can be found here: https://www.eisai.eu/wp-content/uploads/Community-guidelines-v1.0.pdf For more information about how Eisai processes your data, please refer to our privacy policy here: https://www.eisai.eu/privacy-policy/ --- November 2023 | EMEA-NON-23-00180